Cilag AG

Cilag AG is a Swiss pharmaceutical company based in Schaffhausen and a subsidiary of Johnson & Johnson. Its roots go back to a research laboratory established in Schaffhausen in 1933 by Swiss chemist Bernhard Joos. That laboratory provided the foundation for Chemische Industrie-Labor AG, whose abbreviated name became Cilag, founded on 12 May 1936. The company initially combined chemical research with the development of medicinal products and other commercial applications of newly discovered compounds. One of the early compounds associated with Joos was pyridazil, an azo dyestuff derived from pyridine that was developed as an analgesic for the urinary tract. By 1952, Joos had discovered seven new chemical compounds and developed them into products. This early work established a research-oriented identity for Cilag and helped shape its later activities in pharmaceutical discovery, development, and production. Cilag's governance initially included prominent Swiss academic participation. Carl Naegeli, a professor at the Chemical Institute of the University of Zurich, served as the first president of the company's administrative board. Following Naegeli's death in 1942, Bernhard Joos assumed the company's managing role and remained involved until leaving in 1949. A major corporate turning point came in 1959, when Cilag joined the Johnson & Johnson family of companies. The affiliation gave Cilag access to the resources and international reach of a large healthcare group while preserving the company's Swiss operating identity. In the early 1990s, Cilag's marketing organization was combined with that of Janssen Pharmaceuticals to create Janssen-Cilag. Although commercial and marketing activities were integrated under the Janssen-Cilag name in relevant markets, non-marketing functions continued to operate under the original Cilag name. Cilag's work has covered biotechnology, central nervous system medicines, women's health, dermatology, anti-infective therapies, and immunology. The company has continued to maintain activities in Switzerland spanning research and development, manufacturing, and international services. Its role within Johnson & Johnson is associated with the group's Innovative Medicine business segment. In August 2014, Cilag acquired Covagen, a Swiss biopharmaceutical company specializing in multispecific protein-based therapeutics. The transaction provided access to Covagen's lead candidate, COVA 322, a bispecific anti-tumor-necrosis-factor-alpha and anti-interleukin-17A FynomAb then being studied in a Phase I\u2009b psoriasis trial. The acquisition illustrates Cilag's participation in Johnson & Johnson's strategy of adding external biotechnology innovation to its pharmaceutical research portfolio. Today, Cilag is best understood as a Swiss pharmaceutical operating and corporate platform within Johnson & Johnson rather than as a standalone publicly traded company. Its historical identity remains connected to Schaffhausen, while its commercial and scientific activities are linked to the broader Johnson & Johnson Innovative Medicine and Janssen structure.

Cilag's origins lie in the work of Swiss chemist Bernhard Joos, who established a small research laboratory in Schaffhausen in 1933. The laboratory became the basis for Chemische Industrie-Labor AG, founded on 12 May 1936. The abbreviated name of the company, Cilag, derives from this original German name, which can be translated as Chemical Industry Laboratory. The company was created with a strong emphasis on chemical research and the conversion of discoveries into usable products. Carl Naegeli, a professor at the Chemical Institute of the University of Zurich, became the first president of Cilag's administrative board. After Naegeli died in 1942, Joos assumed the company's managing role. He remained in that position until leaving Cilag in 1949. Joos's early research produced pyridazil, an azo dyestuff derived from pyridine that was developed as an analgesic for the urinary tract. By 1952, he had discovered seven new chemical compounds and developed them into products. These activities gave Cilag an early reputation as a research-based pharmaceutical business rather than simply a manufacturing operation. In 1959, Cilag joined the Johnson & Johnson family of companies. This affiliation marked the company's integration into a much larger international healthcare organization. Cilag retained its Swiss identity and continued to operate in Schaffhausen, while benefiting from the broader group's international structure and resources. During the early 1990s, the marketing organizations of Cilag and Janssen Pharmaceuticals were combined to form Janssen-Cilag. This change brought the two companies' commercial operations together in relevant markets. Activities outside marketing, including functions associated with the original company identity, continued under the Cilag name. Cilag consequently developed a dual identity: a historic Swiss pharmaceutical company and an operating component of the wider Johnson & Johnson pharmaceutical network. The company's research and development activities have extended across biotechnology, central nervous system medicine, women's health, dermatology, anti-infective medicine, and immunology. Cilag has also maintained pharmaceutical manufacturing and international service activities in Switzerland. Within Johnson & Johnson, it is associated with the Innovative Medicine business segment. A later expansion of the company's biotechnology interests occurred in August 2014, when Cilag acquired Covagen. Covagen specialized in multispecific protein-based therapeutics. Its lead program, COVA 322, was a bispecific FynomAb directed against tumor necrosis factor alpha and interleukin-17A. At the time of the acquisition, the candidate was being evaluated in a Phase Ib clinical study for psoriasis. The deal connected Cilag with a platform and development program in biologic immunology. Cilag remains an active pharmaceutical organization with Swiss research, development, manufacturing, and international service operations. Its current significance is primarily organizational: it is part of Johnson & Johnson Innovative Medicine and operates alongside the Janssen structure, while preserving the Cilag name and its long-standing connection with Schaffhausen.

• 2014

  Covagen acquisition

  [1]Cilagen.wikipedia.org

  Cilag acquired Swiss biopharmaceutical company Covagen and obtained access to its multispecific protein therapeutics platform and COVA 322 program.

• 1990

  Marketing organizations move toward Janssen-Cilag

  [1]Cilagen.wikipedia.org

  During the early 1990s, the marketing organizations of Cilag and Janssen Pharmaceuticals were combined to form Janssen-Cilag.

• 1959

  Cilag joins Johnson & Johnson

  [1]Cilagen.wikipedia.org

  Cilag became part of the Johnson & Johnson family of companies.

• 1952

  Early compound-development record

  [1]Cilagen.wikipedia.org

  By this year, Joos had discovered seven new chemical compounds and developed them into products.

• 1942

  Bernhard Joos assumes the managing role

  [1]Cilagen.wikipedia.org

  After the death of first board president Carl Naegeli, founder Bernhard Joos took over the company's managing role.

• 1936

  Chemische Industrie-Labor AG is founded

  [1]Cilagen.wikipedia.org

  Chemische Industrie-Labor AG, later known as Cilag, was founded on 12 May 1936.

• 1933

  Bernhard Joos establishes a research laboratory

  [1]Cilagen.wikipedia.org

  Swiss chemist Bernhard Joos established a small research laboratory in Schaffhausen, creating the institutional foundation for Cilag.

Swiss research-led pharmaceutical company operating within Johnson & Johnson Innovative Medicine, with capabilities in drug discovery, development, manufacturing, and international pharmaceutical services.

• Pharmaceutical medicine

  Pyridazil

  Pyridazil was an early Cilag product associated with Bernhard Joos's research. It was an azo dyestuff derived from pyridine and was developed as an analgesic for the urinary tract. It represents the company's early approach of transforming chemical research discoveries into medicinal products.

• Biopharmaceutical development program

  COVA 322

  COVA 322 was Covagen's lead candidate obtained by Cilag through the 2014 acquisition of Covagen. It was described as a bispecific anti-tumor-necrosis-factor-alpha and anti-interleukin-17A FynomAb. At the time of the transaction, it was being evaluated in a Phase Ib study for psoriasis.

• 2014

  Acquire CovagenM&A

  Background

  Covagen specialized in multispecific protein-based therapeutics and had a lead immunology candidate in clinical development.

  Action taken

  Cilag acquired Covagen in August 2014, gaining access to the company's technology platform and COVA 322.

  Aftermath

  The transaction expanded Cilag's access to biotechnology and multispecific biologic drug development, including a psoriasis program.

  Source

• 1990

  Integrate marketing operations with JanssenStrategy

  Background

  Johnson & Johnson operated both Cilag and Janssen Pharmaceuticals, creating an opportunity to coordinate their commercial organizations.

  Action taken

  During the early 1990s, the marketing organizations were combined under the Janssen-Cilag name, while non-marketing activities continued under their original company names.

  Aftermath

  Cilag's commercial identity became linked to Janssen-Cilag in relevant markets, while Cilag continued as an operating name for other activities.

  Source

• 1959

  Join the Johnson & Johnson family of companiesM&A

  Background

  Cilag had developed as a Swiss research-based pharmaceutical company and entered the Johnson & Johnson corporate family in 1959.

  Action taken

  Cilag became a Johnson & Johnson subsidiary while retaining its Swiss operating identity.

  Aftermath

  The relationship connected Cilag to Johnson & Johnson's international healthcare and pharmaceutical organization.

  Source

1. 1Cilagen.wikipedia.org
2. 2Cilag AG official websitecilag.ch